Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5832.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,3186.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1816.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1905.0,1.0,=,1.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1087.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,534.0,1.0,=,2.0
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,874.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,666.0,1.0,=,1.3
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,843.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1084.0,1.0,=,0.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,650.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,565.0,1.0,=,1.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,5658.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,3931.0,1.0,=,1.4
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,4310.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,2766.0,1.0,=,1.6
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,3383.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,471.0,1.0,=,7.2
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2292.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1260.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2247.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1706.0,1.0,=,1.3
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2071.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1909.0,1.0,=,1.1
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1973.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1100.0,1.0,=,1.8
Neerukonda21,10.3390/v13122485,Pseudovirus (HIV),Supplementary Figure S2B,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1865.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,1757.0,1.0,=,1.1